Date: August 18, 2026 Main source: U.S. Food and Drug Administration Link: https://www.fda.gov/news-events/press-announcements/fda-seeks-public-feedback-inform-regulatory-approach-generative-ai-enabled-medical-devices Supplementary sources: https://www.fda.gov/medical-devices/digital-health-center-excellence/considerations-regulation-generative-ai-enabled-medical-devices-discussion-paper-and-request
Summary
The FDA published a discussion paper to collect comments on how it should evaluate medical devices enabled by generative AI. The paper explores risk assessment, premarket review, post-launch monitoring, foundation models and AI systems with agentic capabilities. The agency floats a possible two-axis risk framework and a competence assessment inspired by how professional performance is validated in medicine. The comment period stays open until October 19, 2026.
Why it matters
Medical AI regulation is starting to move from general principles to operational questions about testing, monitoring, model drift and agentic behavior. Companies entering health cannot treat a clinical agent like a conventional SaaS app. Evidence, traceability and continuous monitoring will become part of the product.
Practical implications
- Any agency working in health must clearly separate administrative automation from functions that could become a regulated medical device.
- Record sources, model versions, actions and results from the start, not as a layer added later.
- Teams building clinical AI should review the FDA paper now, even though it is not final guidance yet.